Magnesium L-Carnitine Aqueous Composition Crystallization Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing aqueous magnesium-containing solutions face challenges with crystallization issues due to high magnesium concentrations, making it difficult to achieve storage-stable solutions with high magnesium content.
Innovation Solution
An aqueous composition comprising a magnesium compound, such as magnesium aspartate hydrochloride, combined with L-carnitine, which effectively prevents or delays crystallization, allowing for high magnesium concentrations without stability issues, with preferred ranges of 50-75% magnesium and 5-35% L-carnitine by weight.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high magnesium concentration is used in aqueous solution, then the effectiveness of the medicament is improved, but crystallization occurs making the solution unstable
Solution Approach 1:
L-carnitine acts as a mediator substance that prevents crystallization of magnesium compounds. The patent specifies adding 5-35% by weight of L-carnitine to the aqueous magnesium solution, which interferes with the crystal lattice formation of magnesium salts, thereby maintaining solution stability at high magnesium concentrations (50-75% by weight) that would otherwise crystallize
2Reliability
If magnesium concentration is increased to improve therapeutic effect, then the bioavailability is improved, but the solution becomes unstable due to crystallization
Solution Approach 1:
L-carnitine serves as a stabilizing intermediary that allows high magnesium concentrations (50-75% by weight) to be maintained in aqueous solution without crystallization. This enables the solution to remain storage-stable while achieving high bioavailability, as the magnesium remains in soluble form available for absorption
Solution Approach 2:
The patent changes the chemical composition parameters by adding L-carnitine at specific concentrations (5-35% by weight), which alters the physical-chemical properties of the magnesium solution. This parameter change prevents the phase transition from dissolved to crystalline state, maintaining reliability and storage stability simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves storage stability with high magnesium content, significantly delaying or preventing crystallization, even at high concentrations, and demonstrates enhanced solubility and bioavailability, suitable for use as a medicament or animal feed additive.
Implementation Method 1
by addition of L-carnitine the crystallization of magnesium salts or magnesium complex compounds even in highly concentrated solutions can be effectively prevented or at least significantly delayed
Data Source
AI summary
The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting muscle structure, and its use as food supplement or in the veterinary sector as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels.